News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Hansen Gwenn
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/03/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Sold 1,098 shares
@ $11.75, valued at
$12.9k
Exercised 3,206 restricted stock units
@ $0 |
|
01/21/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Granted 115,438 options to buy
@ $19.49, valued at
$2.2M
Granted 51,308 restricted stock units
@ $0 |
|
01/04/2022 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Sold 1,828 shares
@ $28.96, valued at
$52.9k
Exercised 400 options to buy
@ $7.26, valued at
$2.9k
Exercised 1,428 options to buy
@ $9.57, valued at
$13.7k
|
|
12/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/02/2021 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Sold 400 shares
@ $33.24, valued at
$13.3k
Exercised 400 options to buy
@ $7.26, valued at
$2.9k
|
|
10/28/2021 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Sold 400 shares
@ $35, valued at
$14k
Exercised 400 options to buy
@ $7.26, valued at
$2.9k
|
|
10/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/01/2020 |
4
| Hansen Gwenn (Chief Scientific Officer) has filed a Form 4 on Nurix Therapeutics, Inc.
Txns:
| Exercised 12,000 options to buy
@ $0.84, valued at
$10.1k
|
|
|
|